ASKP1240

DRUG3 trials

Sponsors

Astellas Pharma Global Development, Inc.

Conditions

Healthy VolunteersKidney TransplantationPharmacodynamics of ASKP1240Pharmacokinetics of ASKP1240Psoriasis

Phase 1

Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

CompletedNCT01582399

Astellas Pharma Global Development, Inc.Healthy Volunteers, Pharmacodynamics of ASKP1240, Pharmacokinetics of ASKP1240

Start: 2012-02-29End: 2012-09-30Updated: 2012-12-10

Phase 2

A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

CompletedNCT01585233

Astellas Pharma Global Development, Inc.Psoriasis

Start: 2012-04-30End: 2015-01-07Updated: 2025-11-17

A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients

CompletedNCT01780844

Astellas Pharma Global Development, Inc.Kidney Transplantation

Start: 2013-03-05End: 2017-01-27Updated: 2025-11-21

Related Papers

Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study

American Journal of Transplantation2019-09-1161 citations

A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.

2019-09-0927 citations